Literature DB >> 22356621

Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking.

Rachel J Smith1, Gary Aston-Jones.   

Abstract

The orexin/hypocretin system is involved in several addiction-related behaviors. In the present experiments, we examined the involvement of orexin in heroin reinforcement and relapse by administering the orexin 1 receptor antagonist SB-334867 prior to heroin self-administration or prior to cue-induced or heroin-induced reinstatement of extinguished heroin seeking in male Sprague Dawley rats. SB-334867 (30 mg/kg, intraperitoneal) reduced heroin intake during self-administration under fixed ratio-1 and progressive ratio schedules. SB-334867 also attenuated reinstatement of heroin seeking elicited by cues, but not reinstatement elicited by a heroin prime. These results indicate that orexin antagonism reduces heroin self-administration, and they support a role for orexin in cue-triggered drug relapse.
© 2012 The Authors. European Journal of Neuroscience © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356621      PMCID: PMC3295925          DOI: 10.1111/j.1460-9568.2012.08013.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  55 in total

Review 1.  Regulation of drug intake.

Authors:  W J Lynch; M E Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2001-05       Impact factor: 3.157

2.  Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal.

Authors:  Dan Georgescu; Venetia Zachariou; Michel Barrot; Michihiro Mieda; Jon T Willie; Amelia J Eisch; Masashi Yanagisawa; Eric J Nestler; Ralph J DiLeone
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

3.  Opioids excite dopamine neurons by hyperpolarization of local interneurons.

Authors:  S W Johnson; R A North
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

4.  Blockade of ionotropic glutamatergic transmission in the ventral tegmental area reduces heroin reinforcement in rat.

Authors:  Zheng-Xiong Xi; Elliot A Stein
Journal:  Psychopharmacology (Berl)       Date:  2002-09-05       Impact factor: 4.530

5.  Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size.

Authors:  R Pickens; T Thompson
Journal:  J Pharmacol Exp Ther       Date:  1968-05       Impact factor: 4.030

6.  Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats.

Authors:  R A Wise; P Newton; K Leeb; B Burnette; D Pocock; J B Justice
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

7.  1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.

Authors:  R A Porter; W N Chan; S Coulton; A Johns; M S Hadley; K Widdowson; J C Jerman; S J Brough; M Coldwell; D Smart; F Jewitt; P Jeffrey; N Austin
Journal:  Bioorg Med Chem Lett       Date:  2001-07-23       Impact factor: 2.823

8.  Variability of drug self-administration in rats.

Authors:  Leigh V Panlilio; Jonathan L Katz; Roy W Pickens; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2003-03-18       Impact factor: 4.530

9.  Pharmacological regulation of intravenous cocaine and heroin self-administration in rats: a variable dose paradigm.

Authors:  G J Gerber; R A Wise
Journal:  Pharmacol Biochem Behav       Date:  1989-02       Impact factor: 3.533

Review 10.  Hypocretin (orexin): role in normal behavior and neuropathology.

Authors:  Jerome M Siegel
Journal:  Annu Rev Psychol       Date:  2004       Impact factor: 24.137

View more
  50 in total

1.  Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.

Authors:  Brooke E Schmeichel; Estelle Barbier; Kaushik K Misra; Candice Contet; Joel E Schlosburg; Dimitri Grigoriadis; John P Williams; Camilla Karlsson; Caleb Pitcairn; Markus Heilig; George F Koob; Leandro F Vendruscolo
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  Integration of reward signalling and appetite regulating peptide systems in the control of food-cue responses.

Authors:  A C Reichelt; R F Westbrook; M J Morris
Journal:  Br J Pharmacol       Date:  2015-11-01       Impact factor: 8.739

3.  Hypocretin/orexin antagonists decrease cocaine self-administration by female rhesus monkeys.

Authors:  Richard W Foltin; Suzette M Evans
Journal:  Drug Alcohol Depend       Date:  2018-05-25       Impact factor: 4.492

Review 4.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 6.  Systems level neuroplasticity in drug addiction.

Authors:  Matthew W Feltenstein; Ronald E See
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

7.  Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.

Authors:  Manuel Sanchez-Alavez; Jessica Benedict; Derek N Wills; Cindy L Ehlers
Journal:  Sleep       Date:  2019-04-01       Impact factor: 5.849

8.  Role of orexin/hypocretin in conditioned sucrose-seeking in rats.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

9.  Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice.

Authors:  Kelly Lei; Scott A Wegner; Ji-Hwan Yu; F Woodward Hopf
Journal:  Neuropharmacology       Date:  2016-08-11       Impact factor: 5.250

10.  Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.